终末期肝病模型联合血清钠预测失代偿期肝硬化患者短期预后临床价值.docVIP

终末期肝病模型联合血清钠预测失代偿期肝硬化患者短期预后临床价值 　　[摘要]目的 探讨终末期肝病模型联合血清钠（MELD-Na）预测失代偿期肝硬化患者短期预后的临床价值。方法 选取2012年1月～2015年1月本院消化内科住院的152例肝硬化失代偿期患者，随访3个月，据随访结果，将其分为死亡组43例，生存组109例，分别计算两组患者入院后首次的CTP、MELD及MELD-Na评分，运用受试者工作特征曲线（ROC）面积评价三种评分系统对失代偿期肝硬化患者3个月预后的预测价值。结果 152例失代偿期肝硬化患者，随访3个月内死亡43例，生存组CTP、MELD及MELD-Na评分分别为（8.49±2.27）、（12.57±3.89）分和（14.45±4.91）分，死亡组分别为（10.93±2.72）、（20.99±5.62）分和（24.67±4.89）分，两组比较，差异均有统计学意义（PMELD评分（0.840）分CTP评分（0.754）分（P0.05）。结论 CTP评分、MELD评分和MELD-Na评分均可用来评估失代偿期肝硬化患者的短期预后，而MELD-Na模型评分更能准确地反映患者病情的严重程度，值得临床上应用。 　　[关键词]失代偿期肝硬化；MELD；MELD-Na；血清钠 　　[中图分类号] R657.3+1 [文献标识码] A [文章编号] 1674-4721（2016）06（b）-0032-03 　　Clinical value of end-stage liver disease model combined with MELD-Na in prevention short-term prognosis in patients with decompensated liver cirrhosis 　　LI Hong-yu 　　Department Digestive System，the Second Hospital of Fushun in Liaoning Province，Fushun 113001，China 　　[Abstract]Objective To explore the clinical value of end-stage liver disease model combined with MELD-Na in prevention short-term prognosis in patients with decompensated liver cirrhosis.Methods 152 patients with decompensated liver cirrhosis from January 2012 to January 2015 of digestive system department in our hospital were selected and followed-up for 3 months.According to follow-up results，death group was 43 cases and surviving group was 109 cases.The first value of CTP，MELD and MELD-Na were respectively counted after admission.Receiver operating characteristic curve （ROC） was used to further evaluate three scoring systems on the 3 months later predictive value of decompensated liver cirrhosis patients.Results Among 152 decompensated liver cirrhosis patients，43 death within 3 months followed-up.The CTP，MELD and MELD-Na score in surviving group were respectively （10.93±2.72），（20.99±5.62） and （24.67±4.89），which were respectively （10.93±2.72），（20.99±5.62） and （24.67±4.89） in death group，with significant difference（PMELD score （0.840）CTP（0.754，P0.05）.Conclusion All of CTP scoring，MELD scoring